GAITHERSBURG, Md., April 16,
2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:
YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and
delivering new generations of vaccines and therapeutic biologics
for infectious diseases and cancer, today announced that it plans
to release its financial results for the first nine months of the
fiscal year ended March 31,
2024, before the U.S. market opens on Friday, April 19,
2024.
The Company's management will hold an earnings conference call
at 8:00 A.M. Eastern Time on Friday,
April 19, 2024 to discuss the financial results. Listeners
may access the call by dialing the following numbers:
|
United States Toll
Free:
|
1-888-346-8982
|
|
International:
|
1-412-902-4272
|
|
Mainland China Toll
Free:
|
4001-201203
|
|
Canada Toll Free:
|
1-855-669-9657
|
|
Hong Kong:
|
852-301-84992
|
Upon dialing-in, participants should ask to be joined into the
YS Biopharma Co., Ltd. call.
The replay will be accessible through April 26, 2024 by
dialing the following numbers:
|
United States Toll
Free:
|
1-877-344-7529
|
|
International:
|
1-412-317-0088
|
|
Canada Toll Free:
|
1-855-669-9658
|
|
Access Code:
|
2468327
|
A live and archived webcast of the conference call will also be
available at the Company's investor relations website
at https://investor.ysbiopharm.com/.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to
discovering, developing, manufacturing, and commercializing new
generations of vaccines and therapeutic biologics for infectious
diseases and cancer. It has developed a proprietary PIKA®
immunomodulating technology platform and a series of preventive and
therapeutic biologics with a potential for improved Rabies,
Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS
Biopharma operates in China,
the United States, Singapore and the
Philippines, and is led by a management team that combines
rich local expertise and global experience in the
bio-pharmaceutical industry. For more information, please visit
www.ysbiopharma.com.
Investor Relations Contact
Alyssa Li
Director of Investor Relations
Email: ir@yishengbio.com
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-to-report-first-nine-months-of-fiscal-year-2024-financial-results-on-april-19-2024-302118047.html
SOURCE YS Biopharma Co., Ltd.